Navigation Links
Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Date:3/11/2013

with relapsed or refractory AML, and in two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.

About AstellasAstellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology; Immunology including Transplantation and Infectious Diseases; Oncology; Neuroscience; and DM Complications and Kidney Diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.

About Ambit BiosciencesAmbit is a privately held biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program. Contacts:Ambit Contact:Astellas Contact:David SchullCorporate CommunicationsRusso PartnersTEL: +81-3-3244-3201, FAX: +81-3-5201-7473TEL: 212-845-427http://www
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
2. Astellas to Drive PGA TOURs New Womens Initiative
3. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
7. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
8. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
9. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... builds on company,s suite of tests to evaluate ... a leading clinical-diagnostics and biomedical-research laboratory specializing in ... diagnostic assay designed to help physicians better understand ... The company will introduce the Pneumococcal Antibody ...
... March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") ... it has started patient enrolment in a Phase ... in combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal Investigator is Dr. ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions announced today ... of Microsoft Dynamics GP for a senior living facility in Maine. Having achieved ... living communities in 16 states. This further expansion was again a factor of ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... 2015 , ... On July 22nd the Bradenton Herald reported the ... for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the ... heroin crisis in North Florida. The task force has proposed to instate counselors to ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5
... planned spinoff later this summer , , SAN DIEGO, ... public following the planned spinoff of Cardinal Health,s clinical and ... the occasion by providing opportunities for its global employees to ... "This is an exciting day for our company and employees ...
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, Chief ... on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to ... U.S. / Canada Dial-in Number: 866.272.9941, ... 45596036, Replay Dial-in Number: 888.286.8010, ...
... Women are more vulnerable during certain stages of ... News) -- Fluctuating hormone levels may explain trends ... diseases such as Parkinson,s, schizophrenia, Alzheimer,s, Tourette,s and ... level changes occur at various stages of women,s ...
... amoxicillin in kids, , WEDNESDAY, July 1 (HealthDay News) ... infections in young children increases the risk of recurrent ... the Netherlands who called for more prudent use of ... 63 percent of children given the antibiotic amoxicillin experienced ...
... safety in those who think the same way, research contends ... you believe, new research suggests that you,re likely to surround ... be friends or talking heads on television. , "Never having ... way of protecting your beliefs. It,s a little bit primitive, ...
... WOODLANDS, Texas, July 1 eCardio Diagnostics ... arrhythmia monitoring services, today announced that it has received a ... round of institutional funding since the company was founded in ... marks a milestone in the growth of eCardio," noted Larry ...
Cached Medicine News:Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 2Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:Hormones May Affect Neurological Disease Risk 2Health News:Antibiotics May Boost Risk for Recurrent Ear Infection 2Health News:Your Surroundings Mirror Your Beliefs 2Health News:Your Surroundings Mirror Your Beliefs 3Health News:eCardio Receives Significant Investment in Private Funding from Sequoia Capital 2
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: